Paul Wannamaker

1.4k total citations
16 papers, 1.1k citations indexed

About

Paul Wannamaker is a scholar working on Infectious Diseases, Virology and Pharmacology. According to data from OpenAlex, Paul Wannamaker has authored 16 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 12 papers in Virology and 4 papers in Pharmacology. Recurrent topics in Paul Wannamaker's work include HIV Research and Treatment (12 papers), HIV/AIDS drug development and treatment (11 papers) and HIV/AIDS Research and Interventions (7 papers). Paul Wannamaker is often cited by papers focused on HIV Research and Treatment (12 papers), HIV/AIDS drug development and treatment (11 papers) and HIV/AIDS Research and Interventions (7 papers). Paul Wannamaker collaborates with scholars based in United States, United Kingdom and Australia. Paul Wannamaker's co-authors include Mark S. Shaefer, Denise Sutherland‐Phillips, Cindy Vavro, Edwin DeJesus, Linda Yau, Philip Lackey, Benjamin Young, Nicholaos Bellos, Lisa Patel and Britt Stancil and has published in prestigious journals such as The Lancet, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Paul Wannamaker

15 papers receiving 1.0k citations

Peers

Countries citing papers authored by Paul Wannamaker

Since Specialization

Citations

This map shows the geographic impact of Paul Wannamaker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Wannamaker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Wannamaker more than expected).

Fields of papers citing papers by Paul Wannamaker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Wannamaker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Wannamaker. The network helps show where Paul Wannamaker may publish in the future.

Co-authorship network of co-authors of Paul Wannamaker

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Wannamaker. A scholar is included among the top collaborators of Paul Wannamaker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Wannamaker. Paul Wannamaker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	VH3810109 (N6LS) broadly neutralizing antibody safety, pharmacokinetics, and anti-drug antibody incidence in adults without HIV: phase 1 SPAN study results 2025 ·Antimicrobial Agents and Chemotherapy ·Peter A. Leone, (unknown), Paul Wannamaker, Ralph B. D’Agostino, (unknown), Gabriela Ghita, (unknown), Christina Donatti, Kathryn Brown, Yash Gandhi	0
2	1037. Qualitative Findings from a Hybrid III Implementation-Effectiveness Study to Explore Perspectives of Health-care Staff on Early Implementation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) Injectable HIV treatment in the US (CUSTOMIZE) 2020 ·Open Forum Infectious Diseases ·Maggie Czarnogorski, Cindy Garris, Paul Wannamaker, Ronald D’Amico, (unknown), (unknown), Colleen A. McHorney, (unknown), Michael Wohlfeiler, Gary Sinclair, Leandro Mena, David M. Margolis	1
3	1034. Patient Perspectives on Implementation of a Long-Acting Injectable Antiretroviral Therapy Regimen in HIV US Healthcare Settings: Interim Results from the CUSTOMIZE study 2020 ·Open Forum Infectious Diseases ·Cindy Garris, Ronald D’Amico, Paul Wannamaker, (unknown), Colleen A. McHorney, (unknown), Jason Flamm, Blair Thedinger, Paul Benson, (unknown), Maggie Czarnogorski	1
4	Unexpected Finding of Delayed-Onset Seizures in HIV-Positive, Treatment-Experienced Subjects in the Phase Iib Evaluation of Fosdevirine (Gsk2248761) 2013 ·Antiviral Therapy ·David A. Margolis, Joseph J. Eron, Edwin DeJesus, (unknown), Paul Wannamaker, Britt Stancil, Mark R. Johnson	10
5	Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients 2010 ·HIV Clinical Trials ·Kathleen Squires, Benjamin Young, Edwin DeJesus, (unknown), Daniel Murphy, Denise Sutherland‐Phillips, Henry Zhao, Lisa Patel, Lisa Ross, Paul Wannamaker, Mark S. Shaefer, (unknown)	16
6	Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients 2010 ·AIDS ·Kathleen Squires, Benjamin Young, Edwin DeJesus, Nicholaos Bellos, Daniel Murphy, Henry Zhao, Lisa Patel, Lisa Ross, Paul Wannamaker, Mark S. Shaefer	50
7	Similar Virologic and Immunologic Efficacy With Fosamprenavir Boosted With 100 mg or 200 mg of Ritonavir in HIV-Infected Patients: Results of the LESS Trial 2010 ·HIV Clinical Trials ·Calvin Cohen, Edwin DeJesus, Anthony LaMarca, Benjamin Young, Linda Yau, Lisa Patel, Cindy Vavro, Mary Beth Wire, Paul Wannamaker, Mark S. Shaefer	3
8	A Study of HIV Provider Attitudes Toward HLA-B5701* Testing in the United States 2009 ·AIDS Patient Care and STDs ·Maria Watson, Lisa Patel, Belinda Ha, Paul Wannamaker, Robert L. Cuffe, Mark S. Shaefer	3
9	Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment 2009 ·AIDS ·Kimberly Y. Smith, Parul Patel, Derek M. Fine, Nicholaos Bellos, Louis Sloan, Philip Lackey, Princy Kumar, Denise Sutherland‐Phillips, Cindy Vavro, Linda Yau, Paul Wannamaker, Mark S. Shaefer	167
10	First large, multicenter, open-label study utilizing HLA-B5701 screening for abacavir hypersensitivity in North America 2008 ·AIDS* ·Benjamin Young, Kathleen Squires, Parul Patel, Edwin DeJesus, Nicholaos Bellos, Daniel Berger, Denise Sutherland‐Phillips, Qiming Liao, Mark S. Shaefer, Paul Wannamaker	62
11	High Sensitivity of Human Leukocyte Antigen–B5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients 2008 ·Clinical Infectious Diseases* ·Michael S. Saag, Rukmini Balu, Elizabeth J. Phillips, Philip S. Brachman, Claudia Martorell, William J. Burman, Britt Stancil, Michael Mosteller, Cindy Brothers, Paul Wannamaker, Arlene R. Hughes, Denise Sutherland‐Phillips, S. Mallal, Mark S. Shaefer, (unknown)	290
12	High sensitivity of HLA-B5701 in Whites and Blacks in immunologically-confirmed cases of abacavir hypersensitivity (ABC HSR) 2007 ·Murdoch Research Repository (Murdoch University)* ·Michael S. Saag, Ramani Balu, Philip S. Brachman, Britt Stancil, Michael Mosteller, Paul Wannamaker, Denise Sutherland‐Phillips, Emma Jane Phillips, S. Mallal, Mark S. Shaefer	8
13	The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial 2006 ·The Lancet ·Joseph J. Eron, Patrick Yéni, Joseph Gathe, Vicente Estrada, Edwin DeJesus, Schlomo Staszewski, Philip Lackey, Christine Katlama, Benjamin Young, Linda Yau, Denise Sutherland‐Phillips, Paul Wannamaker, Cindy Vavro, Lisa Patel, (unknown), Mark S. Shaefer	258
14	A prospective, 96‐week study of the impact of Trizivir^®, Combivir^®/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral‐naive patients: effect of sex and ethnicity 2006 ·HIV Medicine ·Princy Kumar, (unknown), Melanie Thompson, Karen T. Tashima, (unknown), Paul Wannamaker, Vanessa C. Williams, Mark S. Shaefer, Gary E. Pakes, Keith A. Pappa, (unknown)	60
15	Twice‐Daily Trizivir versus Combivir‐Abacavir in Antiretroviral‐Experienced Adults with Human Immunodeficiency Virus‐1 Infection: A Formulation‐Switch Trial 2003 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), Margaret A. Fischl, (unknown), Charles Farthing, Melanie Thompson, Nicholaos Bellos, Vanessa C. Williams, Teresa L. Kauf, Paul Wannamaker, Mark S. Shaefer	1
16	The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy???Naive HIV-1-Infected Patients 2003 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·(unknown), (unknown), Glenda Gray, Jeffrey P. Nadler, (unknown), Gladys Sepúlveda, Judith Millard, Paul Wannamaker	120

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact